| Literature DB >> 26035830 |
Pascale Leroy1, Andrea Tham1, Hofer Wong2, Rachel Tenney1, Chun Chen3, Rachel Stiner1, John R Balmes4, Agnès C Paquet5, Mehrdad Arjomandi6.
Abstract
BACKGROUND: Inhalation of ambient levels of ozone causes airway inflammation and epithelial injury.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26035830 PMCID: PMC4452717 DOI: 10.1371/journal.pone.0127283
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Bronchoscopy Subjects Characteristics.
| Subject Characteristics | All Subjects | Non-asthmatic | Asthmatic | p-value |
|---|---|---|---|---|
| Number | 19 | 12 | 7 | - |
| Age (years) | 32.5±7.6 | 31.8±6.0 | 33.7±10.1 | 0.59 |
| Sex (female) (N [%]) | 9 [47%] | 5 [42%] | 4 [57%] | 0.54 |
| Height (cm) | 171±10 | 168±11 | 175±8 | 0.14 |
| BMI (kg/m2) | 25.4±5.0 | 24.8±3.2 | 26.5±7.3 | 0.49 |
| FEV1 (L) | 3.5±0.8 | 3.8±0.8 | 3.1±0.6 | 0.05 |
| FEV1 (% predicted) | 97.9±15.1 | 104.3±14.4 | 87.1±9.3 |
|
| FVC (L) | 4.6±1.0 | 4.6±1.0 | 4.6±1.1 | 0.94 |
| FVC (% predicted) | 102.2±12.7 | 104.9±13.2 | 97.4±11.3 | 0.22 |
| FEV1/FVC ratio | 77.5±10.0 | 82.5±4.4 | 69.0±11.3 |
|
| BSA (m2) | 1.85±0.23 | 1.79±0.21 | 1.95±0.25 | 0.15 |
| Atopy (N [%]) | 15 [79%] | 8 [67%] | 7 [100%] | 0.09 |
| VE (L/min/m2 BSA) with 0 ppb O3 | 22.1±2.2 | 22.6±2.0 | 21.2±2.3 | 0.18 |
| VE (L/min/m2 BSA) with 100 ppb O3 | 22.2±3.5 | 21.8±3.3 | 22.9±3.9 | 0.51 |
| VE (L/min/m2 BSA) with 200 ppb O3 | 22.0±3.4 | 22.7±2.8 | 20.8±4.1 | 0.23 |
Data presented as mean±SD. BMI: body mass index; FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; VE: average minute ventilation during exercise; BSA: body surface area; O3: ozone. P-value is for comparison between asthmatic and non-asthmatic subjects.
Ozone-induced cellular inflammation in airways.
| Cells Recovered in BAL | 0 ppb O3 | 100 ppb O3 | 200 ppb O3 | PE±SEM (x104 cells/ml per 100 ppb increase in O3) | p-value | |
|---|---|---|---|---|---|---|
| Leukocytes (x104 cells/ml) | 20.6±11.5 | 21.5±10.6 | 22.6±8.8 | 0.97±0.87 | 0.26 | |
| Macrophages (x104 cells/ml) | 17.3±10.0 | 17.6±10.0 | 18.1±6.9 | 0.40±0.83 | 0.63 | |
| Neutrophils (x104 cells/ml) | 0.55±0.56 | 0.94±0.91 | 1.51±1.79 |
|
| |
| Lymphocytes (x104 cells/ml) | 2.8±2.0 | 2.7±1.5 | 2.6±2.1 | -0.08±0.24 | 0.72 | |
| Eosinophils (x104 cells/ml) | 0.14±0.17 | 0.23±0.26 | 0.37±0.49 |
|
| |
| Epithelial Cells (x104 cells/ml) | 0.98±1.21 | 0.74±0.93 | 0.88±1.06 | -0.05±0.16 | 0.77 | |
| Squamous Cells (x104 cells/ml) | 0.33±0.26 | 0.18±0.18 | 0.26±0.28 | -0.03±0.04 | 0.43 | |
| RBC (x104 cells/ml) | 10.3±10.0 | 8.0±8.2 | 19.7±39.8 | 4.70±3.83 | 0.22 | |
Data presented as mean ± standard deviation (SD) and parameter estimate ± standard error of mean (PE±SEM) for linear regression models. N = 19; p-values are from the regression model of each BAL inflammatory cell against level of ozone exposure. O3: ozone; RBC: red blood cells. Significant comparisons are shown in bold.
Fig 1Ozone-induced Neutrophilia and Eosinophilia in Bronchoalveolar Lavage.
The changes in bronchoalveolar lavage (BAL) neutrophils and eosinophils from 0 to 200 ppb ozone exposure were not significantly different between the subjects with or without asthma or atopy. The horizontal dashed lines represent the 50% increase in count of neutrophils or eosinophils from 0 to 200 ppb ozone exposure. The shaded gray areas represent the subjects categorized as those without an ozone-induced neutrophilic or eosinophilic response (non-responders).
Differentially Expressed Genes with Increasing Levels of Ozone Exposure.
| Regression Analysis | PADE Pair-wise Analyses | |||||
|---|---|---|---|---|---|---|
| Gene Descriptor | 100 ppb O3 (fold change) | 200 ppb O3 (fold change) | Regression q-value | 0 vs. 100 ppb O3 (fold change) | 100 vs. 200 ppb O3 (fold change) | 0 vs. 200 ppb O3 (fold change) |
|
| ||||||
|
| 2.12 | 5.96 | <0.001 | 2.14 | 2.68 | 5.73 |
|
| 1.21 | 2.82 | 0.03 | 1.26 | 2.31 | 2.9 |
|
| 1.24 | 2.48 | 0.01 | 1.34 | 2.21 | 2.96 |
|
| 1.20 | 2.41 | <0.001 | 1.25 | 2.22 | 2.78 |
|
| 1.17 | 2.24 | <0.001 | 1.19 | 1.98 | 2.36 |
| CD1E | 1.31 | 2.17 | <0.001 | 1.31 | 1.7 | 2.23 |
| MERTK | 1.13 | 2.10 | <0.001 | 1.17 | 1.93 | 2.26 |
|
| 1.24 | 2.08 | <0.001 | 1.24 | 1.7 | 2.11 |
|
| 1.22 | 2.07 | <0.001 | 1.31 | 1.77 | 2.33 |
| RASSF2 | 1.11 | 1.94 | 0.02 | 1.09 | 1.85 | 2.01 |
|
| 1.17 | 1.89 | 0.01 | 1.28 | 1.65 | 2.12 |
| GPR84 | 1.10 | 1.63 | 0.01 | 1.16 | 1.56 | 1.81 |
| ACPP | 1.09 | 1.63 | <0.001 | 1.06 | 1.61 | 1.7 |
| ST8SIA4 | 1.00 | 1.53 | 0.03 | -1.01 | 1.55 | 1.54 |
| MEF2C | -1.01 | 1.52 | 0.02 | -1.03 | 1.59 | 1.54 |
|
| ||||||
|
| 1.43 | 2.65 | <0.001 | 1.48 | 1.75 | 2.59 |
| LAMP3 | 1.28 | 1.82 | <0.001 | 1.31 | 1.4 | 1.84 |
| CCL22 | 1.24 | 1.81 | <0.001 | 1.24 | 1.52 | 1.89 |
| PI3 | 1.21 | 1.70 | 0.04 | 1.26 | 1.52 | 1.91 |
| CX3CR1 | 1.18 | 1.69 | <0.001 | 1.18 | 1.53 | 1.8 |
| MMP9 | 1.31 | 1.68 | 0.01 | 1.36 | 1.33 | 1.82 |
| PRKCB | 1.09 | 1.60 | 0.01 | 1.1 | 1.5 | 1.66 |
| CHST15 | 1.14 | 1.54 | 0.04 | 1.17 | 1.43 | 1.67 |
| ETV5 | 1.22 | 1.51 | 0.02 | 1.25 | 1.24 | 1.55 |
| MGAM | 1.16 | 1.45 | 0.02 | 1.18 | 1.26 | 1.49 |
| MMP8 | 1.20 | 1.45 | 0.03 | 1.25 | 1.2 | 1.5 |
| HSD11B1 | 1.32 | 1.42 | <0.001 | 1.35 | 1.08 | 1.46 |
| ANKH | 1.03 | 1.29 | 0.01 | 1.01 | 1.3 | 1.32 |
| SIGLEC10 | 1.06 | 1.29 | 0.01 | 1.06 | 1.25 | 1.33 |
| SEMA4A | 1.10 | 1.24 | 0.02 | 1.09 | 1.18 | 1.29 |
| PADE Significant Only | ||||||
| STEAP4 | 1.18 | 2.24 | 1.00 | 1.40 | 1.89 | 2.65 |
| GPR183 | 1.19 | 1.95 | 0.07 | 1.18 | 1.69 | 2.00 |
| ANKRD22 | 1.14 | 1.82 | 0.17 | 1.12 | 1.75 | 1.96 |
| CCR2 | 1.04 | 1.73 | 0.34 | -1.01 | 1.79 | 1.78 |
| SERPINB9 | 1.08 | 1.72 | 0.11 | 1.05 | 1.67 | 1.75 |
| C4orf18 | 1.06 | 1.64 | 0.14 | 1.01 | 1.7 | 1.73 |
| CD62L | -1.01 | 1.59 | 1.00 | 1.00 | 1.73 | 1.72 |
| SELL | 1.00 | 1.59 | 1.00 | 1.01 | 1.7 | 1.72 |
| CORO1A | 1.00 | 1.54 | 1.00 | -1.05 | 1.69 | 1.61 |
| CLEC5A | 1.02 | 1.51 | 1.00 | -1.02 | 1.6 | 1.56 |
| SLC25A37 | -1.01 | 1.49 | 0.79 | 1.03 | 1.6 | 1.65 |
|
| 1.13 | 1.48 | 0.06 | 1.11 | 1.42 | 1.57 |
| FAM65B | -1.02 | 1.39 | 1.00 | -1.01 | 1.53 | 1.51 |
| LILRA1 | 1.02 | 1.38 | 0.07 | -1.01 | 1.47 | 1.46 |
| IFITM2 | -1.04 | 1.21 | 1.00 | -1.04 | 1.37 | 1.33 |
The significant differentially expressed genes (DEGs) from both regression and PADE pair-wise analyses are listed with fold changes and q-values from regression analysis, as well as PADE delta values and fold changes by PADE analysis. A fold change of 1.00 would reflect no change. The DEGs are separated into three sections: genes found to be differentially expressed by both linear regression and PADE analyses; genes found to be differentially expressed only by linear regression analysis (q-value), and genes found to be differentially expressed only by PADE delta analysis. For PADE pairwise analyses, only DEGs that were consistently regulated across all three pairwise comparisons with PADE delta values above the significance thresholds in each of the two-group comparisons are shown. P-value for regression analysis fold changes <0.001; PADE Delta significance threshold for FA vs 200 ppb two-group comparison = 0.7; PADE Delta significance threshold for 100 ppb vs 200 ppb two-group comparison = 0.5; PADE Delta significance threshold for FA vs 100 ppb two-group comparison = 0.2. Genes highlighted in bold represent the DEGs whose expressions were also up-regulated in the separate preliminary study of 3 subjects (see Methods and S2 Table).
Fig 2Heatmap of BAL Cell Gene Expression After Ozone Exposure.
A. Ozone exposure had a consistent effect on the gene expression of human BAL cells with up-regulation of a group of genes in a dose-dependent manner from 0 to 100 to 200 ppb. The subjects are presented on the horizontal axis in the same order in each level of exposure. Covariates of atopy, lung function response, neutrophilic response, asthma, and gender are marked above the heatmap, with color indicating presence of covariates (for gender, blue = male; pink = female; for lung function and neutrophilic response, green and blue = no response; see Methods for details). B & C. Cluster analysis identified a relatively distinct classification of subjects with and without asthma or those with and without lung function response to 200 ppb ozone.
Enriched Gene Ontologies From Differentially Expressed Genes Across Ozone Exposures.
| Term | Gene Descriptors | FDR (%) | p-value |
|---|---|---|---|
| GO:0006952~defense response | S100A12, CCL22, LILRA1, CORO1A, CCL2, CCR2, CLEC5A, PLA2G7, CX3CR1, SPP1, IL8RA | 0.01 | 8.6 x 10–6 |
| GO:0006955~immune response | GPR183, CCL22, CD1E, LILRA1, CD1C, CORO1A, CCL2, IL1R2, CCR2, CLEC5A, IFITM2 | 0.03 | 2.4E x 10–5 |
| GO:0006935~chemotaxis | CCL22, CORO1A, CCL2, CCR2, CX3CR1, IL8RA | 0.1 | 1.0 x 10–4 |
| GO:0007626~locomotory behavior | CCL22, ANKH, CORO1A, CCL22, CCR2, CX3CR1, IL8RA | 0.2 | 1.4 x 10–4 |
| GO:0006954~inflammatory response | S100A12, CCL22, CCL2, CCR2, PLA2G7, SPP1, IL8RA | 0.5 | 3.5 x 10–4 |
| hsa04062:Chemokine signaling pathway | CCL22, CX3CR1, CCR2, PRKCB, CCL22, IL8RA | 0.5 | 6.3 x 10–4 |
| GO:0009611~response to wounding | S100A12, CCL22, CCL2, CCR2, PLA2G7, CX3CR1, SPP1, IL8RA | 1.2 | 8.2 x 10–4 |
| GO:0004950~chemokine receptor activity | CCR2, CX3CR1, IL8RA | 2.0 | 1.7 x 10–3 |
| GO:0016021~integral to membrane | ANKH, IL1R2, CLEC5A, MGAM, IFITM2, CD1E, LAMP3, SelectinL, PLXNC1, ACPP, SEMA4A, CHST15, CX3CR1, GPR183, MERTK, C4orf18, SELL, HSD11B1, | 2.4 | 2.2 x 10–3 |
| PIRSF038545:chemokine receptor | CCR2, CX3CR1, IL8RA | 2.5 | 2.8 x 10–3 |
| hsa04060:Cytokine-cytokine receptor interaction | CCL2, CCL22, IL1-R2, CCR2, CX3CR1, IL8RA | 2.6 | 2.9 x 10–3 |
| GO:0019955~cytokine binding | IL1-R2, CCR2, CX3CR1, IL8RA | 2.8 | 2.4 x 10–3 |
| GO:0005886~plasma membrane | S100A12, GPR183, MERTK, ANKH, CORO1A, SELL, PLA2G7, CCR2. CLEC5A, MGAM, PRKCB, IL8RA, KCNJ15, CD1E, LILRA1, CD1C, SelectinL, SIGLEC10 | 5.6 | 5.1 x 10–3 |
| IPR007110:Immunoglobulin-like | CD1E, MERTK, LILRA1, CD1C, IL1R2, SIGLEC10 | 9.1 | 8.2 x 10–3 |
| GO:0005887~integral to plasma membrane | GPR183, CD1E, MERTK, ANKH, CD1C, SELL, CCR2, CLEC5A, SelectinL, CX3CR1, KCNJ15 | 10.4 | 9.8 x 10–3 |
| IPR013151:Immunoglobulin | MERTK, LILRA1, IL1R2, SIGLEC10 | 15.4 | 1.4 x 10–2 |
| GO:0006968~cellular defense response | CCR2, CLEC5A, CX3CR1 | 17.9 | 1.4 x 10–2 |
| GO:0005615~extracellular space | CCL22, CCL2, PLA2G7, SULF2, MMP9, SPP1, MMP8 | 19.1 | 1.9 x 10–2 |
| GO:0015674~di-, tri-valent inorganic cation transport | CORO1A, STEAP4, PRKCB, SLC25A37 | 19.2 | 1.5 x 10–2 |
| GO:0007155~cell adhesion | CORO1A, CCL2, SELL, SIGLAC10, PLXNC1, CX3CR1, SPP1 | 20.3 | 1.6 x 10–2 |
Analysis using DAVID showed 20 enriched gene ontologies to be associated with the DEGs based on linear regression and pair-wise comparison (consistent across all 3 pairs) analyses with FDR threshold <25%.
Fig 3Molecular Function of Processes Associated with the Differentially Expressed Genes (DEGs) After Ozone Exposure.
Analysis using DAVID showed 20 enriched gene ontologies to be associated with the DEGs based on linear regression and two-group comparison analyses with FDR threshold <25%. The gene ontologies are categorized into groups by similar molecular function.
Enriched Gene Ontologies From Differentially Expressed Genes Across 0 and 200 ppb Ozone Exposure.
| Term | Gene Descriptors | FDR (%) | p-value |
|---|---|---|---|
| GO:0005615~extracellular space | IL8, CCL2/mcp-1, HTRA1, PLA2G7, SULF2, MMP9, SPP1, MMP8 | 0.3 | 2.5 x 10–4 |
| GO:0044421~extracellular region part | IL8, CCL2/mcp-1, HTRA1, PLA2G7, PI3, SULF2, MMP9, SPP1, MMP8 | 0.3 | 3.4 x 10–4 |
| hsa04060:Cytokine-cytokine receptor interaction | IL8, CCL2/mcp-1, IL1R2/CD121b, HGF, CX3CR1, IL8RA/CXCR1/CD181 | 0.4 | 4.8 x 10–4 |
| GO:0006954~inflammatory response | S100A12, IL8, CCL2/mcp-1, PLA2G7, SPP1, IL8RA/CXCR1/CD181 | 0.4 | 2. x 10–4 |
| GO:0009611~response to wounding | S100A12, IL8, CCL2/mcp-1, PLA2G7, CX3CR1, SPP1, IL8RA/CXCR1/CD181 | 0.5 | 3.3 x 10–4 |
| GO:0006952~defense response | S100A12, IL8, CCL2/mcp-1, PLA2G7, CX3CR1, SPP1, IL8RA/CXCR1/CD181 | 1.0 | 7.3 x 10–4 |
| GO:0005576~extracellular region | IL8, SPINK1, CCL2/mcp-1, HTRA1, HGF, PLA2G7, PI3, SULF2, MMP9, SPP1, MMP8 | 3.1 | 3.0 x 10–3 |
| GO:0006935~chemotaxis | IL8, CCL2/mcp-1, CX3CR1, IL8RA/CXCR1/CD181 | 4.1 | 3.1 x 10–3 |
| GO:0042330~taxis | IL8, CCL2/mcp-1, CX3CR1, IL8RA/CXCR1/CD181 | 4.1 | 3.1 x 10–3 |
| hsa04062:Chemokine signaling pathway | IL8, CCL2/mcp-1, CX3CR1, IL8RA/CXCR1/CD181 | 10.0 | 1.3 x 10–2 |
| GO:0006955~immune response | IL8, GPR183, CD1E, CD1C, CCL2/mcp-1, IL1R2/CD121b | 10.1 | 7.7 x 10–3 |
| GO:0019955~cytokine binding | IL1R2/CD121b, CS3CR1, IL8RA/CXCR1/CD181 | 15.3 | 1.4 x 10–2 |
| hsa04640:Hematopoietic cell lineage | CD1E, CD1C, IL1R2/CD121b | 16.5 | 2.3 x 10–2 |
| GO:0007626~locomotory behavior | IL8, CCL2/mcp-1, CX3CR1, IL8RA/CXCR1/CD181 | 17.1 | 1.3 x 10–2 |
| GO:0004175~endopeptidase activity | HTRA1, HGF, MMP9, MMP8 | 24.6 | 2.4 x 10–2 |
Analysis using DAVID showed 15 enriched gene ontologies to be associated with the DEGs based on pair-wise comparison between 0 and 200 ppb ozone exposure with FDR threshold <25%.
Gene Set Analysis (GSA) Using Ingenuity Pathway Analysis (IPA).
| Set Name | GSA Score | GSA p-value | GSA FDR (%) |
|---|---|---|---|
| KEGG_HEMATOPOIETIC_CELL_LINEAGE | 0.634 | <0.001 | <0.1 |
| BIOCARTA_CALCINEURIN_PATHWAY | 0.688 | <0.001 | <0.1 |
| BIOCARTA_CCR5_PATHWAY | 0.857 | <0.001 | <0.1 |
| KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION | 0.385 | <0.001 | <0.1 |
| G_PROTEIN_COUPLED_RECEPTOR_BINDING | 0.667 | <0.001 | <0.1 |
| METALLOPEPTIDASE_ACTIVITY | 0.457 | <0.001 | <0.1 |
| CHEMOKINE_ACTIVITY | 0.684 | <0.001 | <0.1 |
| CHEMOKINE_RECEPTOR_BINDING | 0.787 | <0.001 | <0.1 |
| METALLOENDOPEPTIDASE_ACTIVITY | 0.647 | <0.001 | <0.1 |
| BEHAVIOR | 0.499 | <0.001 | <0.1 |
| LOCOMOTORY_BEHAVIOR | 0.690 | <0.001 | <0.1 |
| INFLAMMATORY_RESPONSE | 0.422 | <0.001 | <0.1 |
| RESPONSE_TO_EXTERNAL_STIMULUS | 0.352 | <0.001 | <0.1 |
| RESPONSE_TO_WOUNDING | 0.415 | <0.001 | <0.1 |
| KEGG_ALDOSTERONE_REGULATED_SODIUM_REABSORPTION | 0.483 | 0.002 | 4.5 |
| BIOCARTA_CARDIACEGF_PATHWAY | 0.651 | 0.002 | 4.5 |
| KEGG_CHEMOKINE_SIGNALING_PATHWAY | 0.287 | 0.002 | 4.5 |
GSA identified 17 processes associated with the DEGs from linear regression analysis with FDR threshold <5%.
Fig 4Stratification of BAL Cells Gene Expression After Ozone Exposure by Covariates.
Rate of increase in expression (parameter estimate ±SEM in fold change per 100 ppb increase in level of ozone exposure) of DEGs involved in some of the identified processes from DAVID with stratification for (A) asthma status or (B) lung function response to ozone. O3: ozone.
Fig 5Expression of Osteopontin RNA and Protein in BAL After Ozone Exposure.
A. Osteopontin gene (SPP1) RNA expression increased with increasing ozone exposure (q-value of 9.1x10-7 in linear regression analysis). B. Immunoblot of BAL samples from four representative subjects after exposure to 0, 100, and 200 ppb ozone probed with anti-OPN antibody. C. Osteopontin total protein (monomeric and polymeric forms) signal (from immunoblot densitometry analysis) increased with increasing ozone exposure (linear regression p-value = 0.03). D & E. The ratio of polymeric to monomeric forms of osteopontin decreased with increasing ozone exposure in those subjects with asthma (linear regression p-value = 0.01). Bars represent Mean ± SEM.
Fig 6Effect of Osteopontin on Epithelial Wound Closure.
16HBE14o- cells were grown to confluence on trans-well membrane plates and used in a scratch assay as a model of wound closure. A. Open wound area was measured 14 hours after scratch and treatment with saline (PBS), monomeric osteopontin (mOPN), transglutaminase 2 (TG2), polymeric osteopontin (pOPN), with and without anti-osteopontin antibody (anti-OPN) or anti-α9 integrin antibody (anti-α9). The scale bar is 50 μm. B. Average width of open wound area was calculated by adjusting wound area for length of scratch. The graph shows mean (middle horizontal bar) and standard deviation (whiskers).